In the past decade, changes have occurred in the spectrum of multiple sclerosis courses.
The natural history of multiple sclerosis appears milder from the first sign of demyelinating …

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that
affects nearly 2.8 million people each year. MS distinguishes three main types: relapsing …

E-health and multiple sclerosis : Current Opinion in Neurology E-health and multiple sclerosis :
Current Opinion in Neurology Log in or Register Subscribe to journalSubscribe Get new issue …

Over the last decade, clinical registries have significantly contributed to the pool of evidence
that supports management decisions in patients with multiple sclerosis. Being the largest …

Abstract Background and purpose Reaching Expanded Disability Status Scale (EDSS)≥ 7.0
represents the requirement for a wheelchair. Here we (i) assess the effect of ocrelizumab on …

Multiple sclerosis is an autoimmune disease in which the immune system attacks the myelin
sheath in the central nervous system. It is characterized by blood-brain barrier dysfunction …

Background Disease activity in multiple sclerosis (MS) is defined as presence of relapses,
gadolinium enhancing lesions and/or new or enlarging lesions on MRI. It is associated with …

Abstract Objectives In January 2018, the European Union (EU) approved ocrelizumab in
relapsing multiple sclerosis (RMS) and as the first disease-modifying therapy (DMT) for …

Background: The current standard endpoint to assess disability accumulation in multiple
sclerosis (MS) clinical trials is the time to the first confirmed disability progression, which …

Background There is limited data analyzing the safety and effectiveness of dimethyl
fumarate (DMF) in the progressive multiple sclerosis (PMS) population. Objective To analyze …